Cisplatin (100mg/m2)

DRUG3 trials

Sponsors

Sun Yat-sen University

Conditions

Nasopharangeal CancerNasopharyngeal CancerNasopharyngeal Cancinoma (NPC)Nasopharyngeal Carcinoma

Phase 3

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruitingNCT04907370

Sun Yat-sen UniversityNasopharyngeal Carcinoma

Start: 2021-08-01End: 2027-03-01Updated: 2025-07-16

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07238569

Sun Yat-sen UniversityNasopharangeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2025-12-01End: 2031-05-23Target: 516Updated: 2025-11-20

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Not yet recruitingNCT07373990

Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2026-01-15End: 2030-12-31Target: 418Updated: 2026-01-28

Related Papers

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma

JAMA2025-08-2111 citations

PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.

Journal of Clinical Oncology2025-06-042 citations

Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.

Journal of Clinical Oncology2024-08-10

Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.

Journal of Clinical Oncology2024-06-013 citations

TIRA study: A phase III, multicenter, randomized controlled study of toripalimab plus radical chemoradiotherapy with or without concurrent cisplatin in patients with high-risk locoregionally advanced nasopharyngeal carcinoma.

Journal of Clinical Oncology2022-06-013 citations